VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma

K. S. Tewari; B. J. Monk; I. Vergote; A. Miller; A. C. de Melo; H. S. Kim; Y. M. Kim; A. Lisyanskaya; V. Samouelian; D. Lorusso; F. Damian; C-L. Chang; E. A. Gotovkin; S. Takahashi; D. Ramone; J. Pikiel; J. Li; M. Mathias; M. G. Fury; A. Oaknin

doi:10.1016/j.annonc.2021.04.009

Back

VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma

Journal article

Peer reviewed

VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma

K. S. Tewari, B. J. Monk, I. Vergote, A. Miller, A. C. de Melo, H. S. Kim, Y. M. Kim, A. Lisyanskaya, V. Samouelian, D. Lorusso, …

Annals of oncology, Vol.32(7), pp.940-941

07/01/2021

DOI: https://doi.org/10.1016/j.annonc.2021.04.009

Abstract

Life Sciences & Biomedicine

Oncology

Science & Technology

Metrics

4 Record Views

See more details

Details

Title: VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma
Creators: K. S. Tewari - Univ Calif Irvine, Dept Obstet & Gynecol, Orange, CA 92668 USA
B. J. Monk - Creighton University
I. Vergote - Univ Hosp, Dept Obstet & Gynecol & Gynecol Oncol, Leuven, Belgium
A. Miller - Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
A. C. de Melo - Brazilian Natl Canc Inst, Div Clin Res, Rio De Janeiro, Brazil
H. S. Kim - Seoul Natl Univ Hosp, Dept Obstet & Gynecol, Seoul, South Korea
Y. M. Kim - Seoul Natl Univ Hosp, Dept Obstet & Gynecol, Seoul, South Korea
A. Lisyanskaya - St Petersburg State Budgetary Inst Healthcare, Dept Gynaecol Oncol, St Petersburg, Russia
V. Samouelian - Université de Montréal
D. Lorusso - Fdn Policlin Univ A Gemelli IRCCS, Gynaecol Oncol Unit, Rome, Italy
F. Damian - Hosp Sao Lucas PUCRS, Gynaecol, Porto Alegre, RS, Brazil
C-L. Chang - Mécanique et Engrenage Moderne
E. A. Gotovkin - State Budget Healthcare Inst Ivanovo Reg Oncol Di, Gynaecol, Ivanovo, Russia
S. Takahashi - College Station Medical Center
D. Ramone - Barretos Canc Hosp Pio XII Fdn, Clin Res Dept, Barretos, Brazil
J. Pikiel - Szpitale Pomorskie, Gynaecol, Gdynia, Poland
J. Li - Regeneron
M. Mathias - Regeneron
M. G. Fury - Regeneron
A. Oaknin - Hosp Univ Vall Hebron, Vall Hebron Inst Oncol VHIO, Gynaecol Canc Programme, Vall Hebron Barcelona Hosp Campus, Barcelona, Spain
Publication Details: Annals of oncology, Vol.32(7), pp.940-941
Publisher: Elsevier
Number of pages: 2
Grant note: Regeneron Pharmaceuticals, Inc.; Regeneron Sanofi
Identifiers: 991005969060302656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article

VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma

Abstract

Related links

Metrics

Details